Stockscreener 앱 받기
4.74
0.84%
-0.04
시간 외 거래:
4.78
0.04
+0.84%
전일 마감가:
$4.78
열려 있는:
$4.77
하루 거래량:
57,943
Relative Volume:
0.26
시가총액:
$90.89M
수익:
-
순이익/손실:
$-33.63M
주가수익비율:
-2.4786
EPS:
-1.9124
순현금흐름:
$-47.63M
1주 성능:
-2.07%
1개월 성능:
-11.40%
6개월 성능:
+7.00%
1년 성능:
+38.19%
1일 변동 폭
$4.60
$4.81
1주일 범위
$4.59
$4.94
52주 변동 폭
$3.06
$5.73
폴리피드 Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.74 | 92.80M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
PolyPid Ltd (PYPD) Stock News Today - TradingKey
Conferencia de resultados del 2T de 2026 de PolyPid (PYPD): revisión prioritaria de D-PLEX100 y acuerdo con Azurity - TradingKey
What is HC Wainwright's Forecast for PolyPid Q3 Earnings? - MarketBeat
PolyPid (PYPD) Earnings Call zum 2. Quartal 2026: Prioritäre Prüfung für D-PLEX100 und Azurity-Deal - TradingKey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure - Stock Titan
HC Wainwright Issues Negative Estimate for PolyPid Earnings - MarketBeat
PolyPid Earnings Call: Priority Review, Big Azurity Deal - TipRanks
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance
PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline - TipRanks
PolyPid Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk - Stock Titan
Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99% - Stock Titan
PolyPid Releases Q2 2026 Financial Results - AlphaStreet
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
PolyPid Q2 Earnings Call Highlights - MarketBeat
PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA - scanx.trade
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Australia
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
PolyPid Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
PolyPid Wins FDA Priority Review for D-PLEX₁₀₀ and Locks In $30 Million Azurity Milestones - TipRanks
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028 - tradingview.com
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
PolyPid (PYPD) secures D-PLEX100 FDA priority review and $30M Azurity deal - Stock Titan
PolyPid's D-PLEX100 Deal Includes Up to About $320M in Payments - Stock Titan
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
PYPD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Polypid Gains Nda Acceptance and Priority Review for D-Plex100 and Announces Partnership with Azurity Pharmaceuticals - marketscreener.com
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 - The Manila Times
PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026 - quiverquant.com
PolyPid to report Q2 2026 financial results and hold conference call on August 12, 2026 - Pluang
PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review By Investing.com - Investing.com South Africa
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ - globenewswire.com
FDA grants priority review to PolyPid's D-PLEX1... - Pluang
PolyPid Ltd (PYPD) Balance Sheet - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYPD|PolyPid Ltd|Price:3.950|Chg%:+0.050 - TradingKey
PYPD|PolyPid Ltd|Price:4.290|Chg%:-0.080 - TradingKey
PolyPid Ltd (PYPD) Earnings Date & Reports & Earnings News - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PolyPid Ltd (PYPD) Income Statement - TradingKey
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Expands By 235.2% - MarketBeat
TradingKey - TradingKey
PYPD|PolyPid Ltd|Price:3.980| - TradingKey
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):